Sham surgery controls in Parkinson's disease clinical trials: Views of participants

被引:14
|
作者
Kim, Scott Y. H. [1 ,2 ]
De Vries, Raymond [1 ,3 ]
Holloway, Robert G. [4 ,5 ]
Wilson, Renee [6 ]
Parnami, Sonali [1 ]
Kim, H. Myra [7 ]
Frank, Samuel [8 ]
Kieburtz, Karl [4 ,6 ,9 ]
机构
[1] Univ Michigan, Ctr Bioeth & Social Sci Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Med Educ, Ann Arbor, MI 48109 USA
[4] Univ Rochester, Dept Neurol, Rochester, NY USA
[5] Univ Rochester, Dept Community & Prevent Med, Rochester, NY USA
[6] Univ Rochester, Ctr Human Expt Therapeut, Rochester, NY USA
[7] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA
[8] Boston Univ, Dept Neurol, Boston, MA 02215 USA
[9] Univ Rochester, Dept Environm Med, Rochester, NY USA
基金
美国国家卫生研究院;
关键词
sham surgery; gene therapy; Parkinson's disease; bioethics; DOUBLE-BLIND; ETHICS;
D O I
10.1002/mds.25155
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Sham surgery controls are increasingly used in neurosurgical clinical trials in Parkinson's disease (PD) but remain controversial. We interviewed participants of such trials, specifically examining their understanding and attitudes regarding sham surgery. Methods: We conducted semistructured qualitative interviews with participants of 3 sham surgerycontrolled trials for PD, focusing on their understanding of sham design, their reactions to it, its impact on decision making, and their understanding of posttrial availability of the experimental intervention and its impact on decisions to participate. Results: All subjects (n = 90) understood the 2-arm design; most (86%) described the procedural differences between the arms accurately. Ninety-two percent referred to scientific or regulatory reasons as rationales for the sham control, with 62% specifically referring to the placebo effect. Ninety-one percent said posttrial availability of the experimental intervention had a strong (48%) or some (43%) influence on their decision to participate, but only 68% understood the conditions for posttrial availability. Conclusions: Most subjects in sham surgerycontrolled PD trials comprehend the sham surgery design and its rationale. Although there is room for improvement, most subjects of sham surgery trials appear to be adequately informed. (c) 2012 Movement Disorder Society
引用
收藏
页码:1461 / 1465
页数:5
相关论文
共 50 条
  • [1] Comparison of enrollees and decliners of Parkinson disease sham surgery trials
    Kim, Scott Y. H.
    Wilson, Renee M.
    Kim, H. Myra
    Holloway, Robert G.
    De Vries, Raymond G.
    Frank, Samuel A.
    Kieburtz, Karl
    MOVEMENT DISORDERS, 2012, 27 (04) : 506 - 511
  • [2] THE ETHICS OF SHAM SURGERY IN PARKINSON'S DISEASE: BACK TO THE FUTURE?
    Swift, Teresa
    Huxtable, Richard
    BIOETHICS, 2013, 27 (04) : 175 - 185
  • [3] Evidence-Based Evaluation of the Ethics of Sham Surgery for Parkinson's Disease
    Polgar, Stephen
    Mohamed, Sheeza
    JOURNAL OF PARKINSONS DISEASE, 2019, 9 (03) : 565 - 574
  • [4] Placebo Surgery in Clinical Research Trials for Parkinson Disease
    Dunlop, Susan Rebecca
    McCormick, Margaret
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2015, 11 (02): : 240 - 247
  • [5] Procedure-Related Complications in Sham Surgeries for Parkinson's Clinical Trials: A Meta-analysis
    Mamaril-Davis, James C.
    Gelb, Adrian W.
    Larson, Paul S.
    MOVEMENT DISORDERS, 2023, 38 (07) : 1223 - 1235
  • [6] Current Therapies in Clinical Trials of Parkinson's Disease: A 2021 Update
    Prasad, E. Maruthi
    Hung, Shih-Ya
    PHARMACEUTICALS, 2021, 14 (08)
  • [7] Network modulation following sham surgery in Parkinson's disease
    Ko, Ji Hyun
    Feigin, Andrew
    Mattis, Paul J.
    Tang, Chris C.
    Ma, Yilong
    Dhawan, Vijay
    During, Matthew J.
    Kaplitt, Michael G.
    Eidelberg, David
    JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (08) : 3656 - 3666
  • [8] Minority enrollment in Parkinson's disease clinical trials
    Schneider, Myra G.
    Swearingen, Christopher J.
    Shulman, Lisa M.
    Ye, Jian
    Baumgarten, Mona
    Tilley, Barbara C.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 (04) : 258 - 262
  • [9] Patient Diaries As a Clinical Endpoint in Parkinson's Disease Clinical Trials
    Papapetropoulos, Spyridon
    CNS NEUROSCIENCE & THERAPEUTICS, 2012, 18 (05) : 380 - 387
  • [10] New Clinical Trials for Nonmotor Manifestations of Parkinson's Disease
    Schrag, Anette
    Sauerbier, Anna
    Chaudhuri, Kallol Ray
    MOVEMENT DISORDERS, 2015, 30 (11) : 1490 - 1503